insulin-to-HDL-C ratio

1. insulin-to-HDL-C ratio predicts metabolic dysfunction-associated steatotic liver disease in humans (AUROC 0.759, 95% CI 0.737–0.782).

   Humansn = 1,735

   Insulin-to-HDL-C Ratio as a Simple and Reliable Surrogate Marker of Metabolic dysfunction-associated steatotic liver disease Prevalence, Steatosis Severity, and Metabolic Burden: A Cross-Sectional Comparison with Established Insulin Resistance Indices

   Research Square·25 Aug 2026Preprint

2. insulin-to-HDL-C ratio raises the risk of metabolic dysfunction-associated steatotic liver disease in humans (OR 4.80, 95% CI 3.24–7.17).

   Humanshighest versus lowest IHR quartile, multivariable-adjusted modeln = 1,735

   Insulin-to-HDL-C Ratio as a Simple and Reliable Surrogate Marker of Metabolic dysfunction-associated steatotic liver disease Prevalence, Steatosis Severity, and Metabolic Burden: A Cross-Sectional Comparison with Established Insulin Resistance Indices

   Research Square·25 Aug 2026Preprint

More on Metabolic dysfunction-associated steatotic liver disease

1. insulin-to-HDL-C ratio is associated with hepatic steatosis severity in humans.

   Humansn = 1,735

   Insulin-to-HDL-C Ratio as a Simple and Reliable Surrogate Marker of Metabolic dysfunction-associated steatotic liver disease Prevalence, Steatosis Severity, and Metabolic Burden: A Cross-Sectional Comparison with Established Insulin Resistance Indices

   Research Square·25 Aug 2026Preprint